Updated Jul 16, 2026
Lee Sung has filed 5 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $2.51M.
Sung Lee is the Executive Vice President and Chief Financial Officer of Cytokinetics Inc, a biopharmaceutical company focused on developing treatments for muscle-related diseases. He has been involved in the company's financial operations and strategic planning.
| Role | EVP, Chief Financial Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-02 | CYTK | CYTOKINETICS INC | S — Open-market sale | 1.1K | $87.79 | $98K |
| 2026-07-02 | CYTK | CYTOKINETICS INC | M — Option exercise | 1.1K | $48.51 | $54K |
| 2026-06-29 | CYTK | CYTOKINETICS INC | S — Open-market sale | 3.1K | $85.00 | $266K |
| 2026-06-29 | CYTK | CYTOKINETICS INC | M — Option exercise | 823 | $44.36 | $37K |
| 2026-06-29 | CYTK | CYTOKINETICS INC | M — Option exercise | 188 | $44.36 | $8K |
| 2026-06-29 | CYTK | CYTOKINETICS INC | M — Option exercise | 1.1K | $48.51 | $54K |
| 2026-06-29 | CYTK | CYTOKINETICS INC | M — Option exercise | 822 | $44.36 | $36K |
| 2026-06-29 | CYTK | CYTOKINETICS INC | M — Option exercise | 188 | $44.36 | $8K |
| 2026-06-08 | TNGX | Tango Therapeutics, Inc. | A — Grant or award | 570 | $0.00 | |
| 2026-05-05 | CYTK | CYTOKINETICS INC | S — Open-market sale | 23.9K | $76.87 | $1.84M |
| 2026-05-01 | TNGX | Tango Therapeutics, Inc. | A — Grant or award | 12.3K | $0.00 | |
| 2026-03-18 | CYTK | CYTOKINETICS INC | S — Open-market sale | 4.9K | $62.15 | $307K |
| 2026-03-17 | CYTK | CYTOKINETICS INC | A — Grant or award | 20.6K | $0.00 | |
| 2026-01-06 | TNGX | Tango Therapeutics, Inc. | A — Grant or award | 10.0K | $0.00 | |
| 2025-12-29 | CYTK | CYTOKINETICS INC | F — Tax withholding / forfeiture | 805 | $62.72 | $50K |
| 2025-12-29 | CYTK | CYTOKINETICS INC | A — Grant or award | 2.2K | $0.00 | |
| 2025-12-29 | CYTK | CYTOKINETICS INC | A — Grant or award | 2.2K | $0.00 | |
| 2025-12-05 | CYTK | CYTOKINETICS INC | F — Tax withholding / forfeiture | 1.6K | $65.02 | $101K |
| 2025-06-02 | CYTK | CYTOKINETICS INC | F — Tax withholding / forfeiture | 5.0K | $31.21 | $155K |
| 2024-12-05 | CYTK | CYTOKINETICS INC | A — Grant or award | 4.3K | $0.00 |
Sung Lee is the Executive Vice President and Chief Financial Officer of Cytokinetics Inc, a biopharmaceutical company focused on developing treatments for muscle-related diseases. He has been involved in the company's financial operations and strategic planning.…
5 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 4 open-market sales ($2.51M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Lee Sung profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.